Lyophilisation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-17. Numbers and descriptions here follow the published literature rather than marketing material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Although they have been determined to be receptors to certain ligands from opioids, their role is not yet fully understood. When opioids are ingested, the ligand binds to these constitutively active receptors to reduce neural activity. This is accomplished by inhibiting adenylyl cyclase and cyclic AMP, which are necessary for communication within the central nervous system. There is research indicating that opioids reduce pain by disrupting ion channels and vesicle fusion. Prolonged exposure to opioids can cause these receptors to become internalized, leading to increased tolerance and increased opioid use.
=== Lupus === As of 2016, studies in cells, animals, and humans have suggested that mTOR activation is a process underlying systemic lupus erythematosus and that inhibiting mTOR with rapamycin may be a disease-modifying treatment. As of 2016 rapamycin had been tested in small clinical trials in people with lupus.
=== Growth Factors === Growth Factor enhanced grafts are produced using recombinant DNA technology. They consist of either Human Growth Factors or Morphogens (Bone Morphogenic Proteins in conjunction with a carrier medium, such as collagen).
Zoltan Galántai recognizes the important role that Kardashev's classification has played in the SETI program, but he believes that another scale is possible, without using energy consumption, by resorting to miniaturization. The hypothesis of Donald Tarter, researcher at SETI, is that a civilization based on nanotechnology would not need an ever-increasing amount of energy. A Type I civilization that masters local space travel could colonize its planetary system and even the Oort cloud without needing an amount of energy that would make it Type II. This scale loses its meaning beyond Type II, since it is impossible to predict the evolution of civilizations over long distances in a galactic colonization process. Finally, Tarter states that the Kardashev scale is the product of an era of insufficient scientific knowledge, which considered the possibility of stellar object CTA-102 as an artificial Type III source, whereas today we know that it is a galactic nucleus. In another article, Zoltan Galántai suggests considering another scale, no longer based on energy consumption, but on a civilization's ability to survive natural and cosmic disasters. Type I would describe a civilization capable of surviving a local natural disaster, like the Anasazi. A Type II civilization would have the means to withstand a regional or continental disaster, and finally Type III could face a global disaster such as an asteroid's impact, a supervolcano's eruption, or an ice age. Beyond the first three types are civilizations that have scattered throughout the galaxy.
=== Extra-articular symptoms === Autonomic dysfunction/dysautonomia: Symptoms may include orthostatic intolerance, dizziness, palpitations, Raynaud's phenomenon, and postural orthostatic tachycardia syndrome (POTS). Functional gastrointestinal disorders: Symptoms such as nausea, vomiting, diarrhea, constipation, bloating, early satiety, reflux, and irritable bowel syndrome. Pelvic and bladder dysfunction: Symptoms include pelvic pain, dyspareunia, bladder dysfunction, organ prolapse, and association with conditions like polycystic ovaries, fibroids, or endometriosis. Fatigue: Profound fatigue, often linked to sleep disturbances, non-restorative sleep, and nocturnal musculoskeletal pain, affecting concentration and quality of life. Mood disorders: Anxiety, depression, panic attacks, and emotional distress, often related to chronic pain and reduced physical function. Symptom expression varies widely, with different combinations and severities seen in individuals. Symptoms may fluctuate over time, often triggered by physical exertion, stress, illness, or injury.
Sources: en.wikipedia.org
Einsteinium is a synthetic, silvery, radioactive metal. In the periodic table, it is located to the right of the actinide californium, to the left of the actinide fermium and below the lanthanide holmium with which it shares many similarities in physical and chemical properties. Its density of 8.84 g/cm3 is lower than that of californium (15.1 g/cm3) and is nearly the same as that of holmium (8.79 g/cm3), despite einsteinium being much heavier per atom than holmium. Einsteinium's melting point (860 °C) is also relatively low—below californium (900 °C), fermium (1,527 °C) and holmium (1,461 °C). Einsteinium is a soft metal, with a bulk modulus of only 15 GPa, one of the lowest among non-alkali metals. Unlike the lighter actinides californium, berkelium, curium and americium, which crystallize in a double hexagonal structure at ambient conditions; einsteinium is believed to have a face-centered cubic (fcc) symmetry with the space group Fm3m and the lattice constant a = 575 pm. However, there is a report of room-temperature hexagonal einsteinium metal with a = 398 pm and c = 650 pm, which converted to the fcc phase upon heating to 300 °C. The self-damage induced by the radioactivity of einsteinium is so strong that it rapidly destroys the crystal lattice, and the energy release during this process, 1000 watts per gram of 253Es, induces a visible glow. These processes may contribute to the relatively low density and melting point of einsteinium.
== "The Triumph of Vulgar Rationalism" (2012) == Amid intense public debate surrounding the Cologne Regional Court's 2012 ruling on circumcision, Kermani published an article in the daily newspaper Süddeutsche Zeitung titled "The Triumph of Vulgar Rationalism". In this article, Kermani accused the Cologne Regional Court of "casually and in the blink of an eye declaring four thousand years of religious history obsolete". The Enlightenment, Kermani argues, does not merely signify the rule of reason, but also an acknowledgment of reason's limitations. "Then again, vulgar rationalism—as expressed in the Cologne Regional Court's ruling—elevates one's own, that is, contemporary, understanding to an absolute, unconditional value." Joachim Gauck has since adopted the term vulgar rationalism in his statements on the circumcision debate.
==== Clinical Laboratory Improvement Amendments (CLIA) ==== CMS ensures the integrity of laboratories performing testing via inspections and consistent oversight, bolstered with proficiency testing by accredited organizations. CLIA authorizes regulation of laboratories that conduct testing, not the individuals who order the tests or receive test results. All laboratories performing DTC testing must obtain CLIA certification and maintain compliance with national standards.
== Compounds == Most metal carbonyl complexes contain a mixture of ligands. Examples include the historically important IrCl(CO)(P(C6H5)3)2 and the antiknock agent (CH3C5H4)Mn(CO)3. The parent compounds for many of these mixed ligand complexes are the binary carbonyls, those species of the formula [Mx(CO)n]z, many of which are commercially available. The formulae of many metal carbonyls can be inferred from the 18-electron rule.
Sources: en.wikipedia.org
== Recombinant protein design == The earliest applications of recombinant protein design can be documented in the use of single peptide tags for purification of proteins in affinity chromatography. Since then, a variety of fusion protein design techniques have been developed for applications as diverse as fluorescent protein tags to recombinant fusion protein drugs. Three commonly used design techniques include tandem fusion, domain insertion, and post-translational conjugation.
=== Liquid chromatography EI-MS === Two recent approaches for coupling capillary scale liquid chromatography-electron ionization mass spectrometry (LC-EI-MS) can be incorporated for the analysis of various samples. These are capillary-scale EI-based LC/MS interface and direct-EI interface. In the capillary EI the nebulizer has been optimized for linearity and sensitivity. The direct-EI interface is a miniaturized interface for nano- and micro-HPLC in which the interfacing process takes place in a suitably modified ion source. Higher sensitivity, linearity, and reproducibility can be obtained because the elution from the column is completely transferred into the ion source. Using these two interfaces electron ionization can be successfully incorporated for the analysis of small and medium-sized molecules with various polarities. The most common applications for these interfaces in LC-MS are environmental applications such as gradient separations of the pesticides, carbaryl, propanil, and chlorpropham using a reversed phase, and pharmaceutical applications such as separation of four anti-inflammatory drugs, diphenyldramine, amitriptyline, naproxen, and ibuprofen. Another method to categorize the applications of electron ionization is based on the separation technique which is used in mass spectroscopy. According to this category most of the time applications can be found in time of flight (TOF) or orthogonal TOF mass spectrometry (OA-TOF MS), Fourier transform ion cyclotron resonance (FT-ICR MS) and quadrupole or ion trap mass spectrometry.
=== Polling === In October, before the strikes, a poll by AtlasIntel showed that approximately 64% of Venezuelans abroad support US military intervention to depose Maduro, compared with 34% within Venezuela. In December, a poll by Datanalisis found that 55% of Venezuelans opposed foreign military intervention while 23% supported it. After the strikes, a poll by Reuters surveying 1,248 adults in the United States found that 33% of Americans approved of the military action, while 34% did not; 65% of Republicans supported the action compared to 11% of Democrats, and 72% of Americans were concerned that the US would get too involved in Venezuela, including 54% of Republicans. The same poll showed that Trump approval ratings rose to 42% after the attack, the highest rating since October 2025, when his approval rating was 39%. A poll was made by The Economist on 9 January, surveying 600 Venezuelan residents of different ages and sex to reflect the national population. Most respondents were positive about the intervention, only 13% of respondents mildly opposed the capture of Maduro. The 18% of respondents oppose United States governance in Venezuela. Most respondents want a quick change of government, with 43% supporting María Corina Machado as the leader and 13% supporting Delcy Rodríguez. The 91% of respondents answering in support for a change of government within a year.
=== Circulating angiogenic cell === A similar method is to culture the peripheral blood mononuclear fraction in supplemented endothelial growth medium, removing the non-adherent cells, and isolating the remaining. While these cells display some endothelial characteristics, they do not form colonies.
=== Depression and bipolar depression === Candesartan is currently being investigated as a potential adjunct therapy for both depression and bipolar depression in the CADET (Candesartan Adjunctive Trials) clinical trials. These studies—one for major depressive disorder and one for bipolar depression—are double-blind, placebo-controlled clinical trials. The proposed mechanism of action is via antagonism of the AT-1 receptor, which a 2017 meta-analysis indicated may have effects on mental health. As Candesartan is a strong AT-1 receptor antagonist, it was selected for the clinical trial.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.